Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-5.35	-69.41	-51.93	-94.23	-282.02
Depreciation & Amortization	1.27	37.5	37.63	37.7	37.97
Stock-Based Compensation	11.28	7.78	9.32	17.85	22.74
Other Adjustments	44.31	23.15	2.32	-33.03	73.97
Change in Receivables	-14.14	4.05	0.99	11.3	-24.03
Changes in Inventories	-23.13	-28.4	-2.54	19.09	-24.95
Changes in Accounts Payable	3.08	-1.36	-5.24	1.5	-11.74
Changes in Accrued Expenses	48.53	-12.78	-10.02	-38.01	-22.08
Changes in Unearned Revenue	2.68	-	-3.74	4.65	1.82
Changes in Other Operating Activities	-0.55	-1.18	-0.18	0.02	-24.64
Operating Cash Flow	67.99	-40.66	-23.38	-73.15	-252.97
Capital Expenditures	-0.29	-0.03	-	-0.11	-0.06
Sale of Property, Plant & Equipment	0.17	-	-	-	-
Purchases of Intangible Assets	-7.81	-	-	-	-
Proceeds from Sale of Investments	-	-	-	-	40
Investing Cash Flow	-7.93	-0.03	-	-0.11	39.94
Long-Term Debt Issued	10	45	-	-	-
Long-Term Debt Repaid	-1.61	-37.1	-32	-33	-
Net Long-Term Debt Issued (Repaid)	8.39	7.9	-32	-33	-
Issuance of Common Stock	68.36	43.03	6.79	7.6	88.95
Net Common Stock Issued (Repurchased)	68.36	43.03	6.79	7.6	88.95
Other Financing Activities	-3.83	-1.27	-	40	44.78
Financing Cash Flow	72.93	49.66	-25.21	14.6	133.73
Net Cash Flow	132.99	8.97	-48.59	-58.67	-79.29
Free Cash Flow	67.7	-40.69	-23.38	-73.27	-253.02
FCF Margin	28.66%	-25.40%	-12.02%	-25.05%	-119.55%
Free Cash Flow Per Share	0.26	-0.19	-0.12	-0.40	-1.52
Levered Free Cash Flow	34.64	-67.76	-68.02	-102.38	-325.7
Unlevered Free Cash Flow	65.35	-56.72	-30.35	-55.94	-308.18

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q